Emerging drugs for active tuberculosis

被引：47

作者：

Ginsberg, Ann M. ^{[1
]}

机构：

[1] Global Alliance TB Drug Dev, Clin Dev, New York, NY 10005 USA

来源：

SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE | 2008年 / 29卷 / 05期

关键词：

tuberculosis; treatment; clinical development; drug resistance;

D O I：

10.1055/s-0028-1085706

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

Tuberculosis (TB) drug research and development lay largely fallow from the 1960s to the turn of the century. A realization that current treatments for this major public health epidemic are proving inadequate to control the disease and prevent development and spread of drug resistance has stimulated renewed activity during the past 5 to 10 years. As a result, there are now seven drugs in clinical development for TB and many groups working on discovery-stage projects. This article summarizes the published information available on the seven clinical candidates and describes some of the challenges faced by those pursuing research and development of novel TB therapies.

引用

页码：552 / 559

页数：8

共 70 条

[1] In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis [J].

Alvirez-Freites, EJ ;

Carter, JL ;

Cynamon, MH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) :1022-1025

[2] A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis [J].

Andries, K ;

Verhasselt, P ;

Guillemont, J ;

Göhlmann, HWH ;

Neefs, JM ;

Winkler, H ;

Van Gestel, J ;

Timmerman, P ;

Zhu, M ;

Lee, E ;

Williams, P ;

de Chaffoy, D ;

Huitric, E ;

Hoffner, S ;

Cambau, E ;

Truffot-Pernot, C ;

Lounis, N ;

Jarlier, V .

SCIENCE, 2005, 307 (5707) :223-227

[3]

[Anonymous], 2003, AM J RESP CRIT CARE, V167, P603

[4]

[Anonymous], 2008, Global tuberculosis control: surveillance, planning, financing

[5]

[Anonymous], 2008, 4 WHO

[6]

Arora S., 2004, 44 INT C ANT AG CHEM

[7] Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis:: Functional analysis of mutant enzymes [J].

Aubry, A ;

Veziris, N ;

Cambau, E ;

Truffot-Pernot, C ;

Jarlier, V ;

Fisher, LM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (01) :104-112

[8] First functional characterization of a singly expressed bacterial type II topoisomerase:: The enzyme from Mycohacterium wherculosis [J].

Aubry, Alexandra ;

Fisher, L. Mark ;

Jarlier, Vincent ;

Cambau, Ernmanuelle .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 348 (01) :158-165

[9] The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism -: Novel insights into drug mechanisms of action [J].

Boshoff, HIM ;

Myers, TG ;

Copp, BR ;

McNeil, MR ;

Wilson, MA ;

Barry, CE .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (38) :40174-40184

[10] Selective killing of nonreplicating mycobacteria [J].

Bryk, Ruslana ;

Gold, Benjamin ;

Venugopal, Aditya ;

Singh, Jasbir ;

Samy, Raghu ;

Pupek, Krzysztof ;

Cao, Hua ;

Popescu, Carmen ;

Gurney, Mark ;

Hotha, Srinivas ;

Cherian, Joseph ;

Rhee, Kyu ;

Ly, Lan ;

Converse, Paul J. ;

Ehrt, Sabine ;

Vandal, Omar ;

Jiang, Xiuju ;

Schneider, Jean ;

Lin, Gang ;

Nathan, Carl .

CELL HOST & MICROBE, 2008, 3 (03) :137-145

← 1 2 3 4 5 6 7 →